Georg H Pfeiler - Gynecology

Author Information

Dr. Georg H. Pfeiler is affiliated with the Department of Obstetrics and Gynecology, Division of General Gynecology and Gynecologic Oncology at the Medical University of Vienna, Austria. His extensive research focuses on breast cancer, particularly in early-stage and hormone receptor-positive cases. He has contributed significantly to the understanding of adjuvant therapies and their effects, including the use of CDK4/6 inhibitors and the impact of concomitant statin treatment.

Research Contributions

Dr. Pfeiler has made substantial contributions to the field of gynecology and oncology through his research on breast cancer. His work spans various aspects of breast cancer treatment, including the efficacy and safety of adjuvant therapies, the impact of patient characteristics on treatment outcomes, and innovative approaches to treatment sequencing. His involvement in multiple clinical trials, such as the PALLAS and ABCSG trials, underscores his commitment to advancing breast cancer treatment and improving patient outcomes. Notable studies include the final results from the randomized phase III PALLAS trial and the post hoc analysis of ABCSG-18, which have provided critical insights into adjuvant therapy strategies.

Aliases

Dr. Georg H. Pfeiler is also known by several aliases, including G Pfeiler, Georg Pfeiler, and G. H. Pfeiler.

Publication and Citation Metrics

Metric	Value
Total Papers	180
Citation Count	5069
h-index	36

Publications:

Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

DOI: 10.1158/1538-7445.sabcs21-gs1-07

Year: 2022

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.

DOI: 10.1016/j.esmoop.2022.100426

Year: 2022

Abstract P1-15-01: Effect of concomitant statin treatment in postmenopausal patients with hormone-receptor positive early-stage breast cancer receiving adjuvant denosumab or placebo: A post-hoc analysis of ABCSG-18

DOI: 10.1158/1538-7445.sabcs21-p1-15-01

Year: 2022

Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial

DOI: 10.1158/1538-7445.sabcs21-p4-12-01

Year: 2022

Abstract P1-02-07: Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSG 24 and 34 trials

DOI: 10.1158/1538-7445.sabcs21-p1-02-07

Year: 2022

Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic

DOI: 10.1016/S1470-2045(21)00708-7

Year: 2022

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

DOI: 10.1200/JCO.21.02554

Year: 2021

Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

DOI: 10.1159/000516157

Year: 2021

Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in the MGMT Promoter by High Resolution Melting Analysis Coupled with Pyrosequencing Using A Single Primer Set

DOI: 10.3390/ijms222212527

Year: 2021

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34

DOI: 10.1038/s41416-021-01284-2

Year: 2021

Why Are Silent Conditions Dangerous?

Can Therapy Be Avoided?

How Do Cultural and Societal Factors Influence Gynecological Care?

How Can Gynecologists Identify and Address Dependency?

How is Beta hCG Measured?

Why is Preconception Screening Important?

How Can Gynecologists Network Effectively on LinkedIn?

What is Spinal Stability?

Are There Guidelines to Manage C-Section Rates?

How can lifestyle changes contribute to risk reduction?

Partnered Content Networks

Relevant Topics